{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:34:32Z","timestamp":1781530472930,"version":"3.54.1"},"reference-count":190,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Background: Since the 1990s, transplantations of hematopoietic and mesenchymal stem cells (HSCT and MSCT) and dendritic cell (DCT) have been investigated for the treatment of neurological autoimmune disorders (NADs). With the growing number of transplanted patients, awareness of neuroimmunolgical complications has increased. Therefore, an overview of SCT for the most common NADs and reports of secondary immunity after SCT is provided. Methods: For this narrative review, a literature search of the PubMed database was performed. A total of 86 articles reporting on different SCTs in NADs and 61 articles dealing with immune-mediated neurological complications after SCT were included. For multiple sclerosis (MS), only registered trials and phase I\/II or II studies were considered, whereas all available articles on other disorders were included. The different transplantation procedures and efficacy and safety data are presented. Results: In MS patients, beneficial effects of HSCT, MSCT, and DCT with a decrease in disability and stabilization of disease activity have been reported. These effects were also shown in other NADs mainly in case reports. In seven of 132 reported patients with immune-mediated neurological complications, the outcome was fatal. Conclusions: Phase III trials are ongoing for MS, but the role of SCT in other NADs is currently limited to refractory patients due to occasional serious complications.<\/jats:p>","DOI":"10.3390\/cells11142165","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T21:57:53Z","timestamp":1657576673000},"page":"2165","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-5674","authenticated-orcid":false,"given":"Franz Felix","family":"Konen","sequence":"first","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1260-1650","authenticated-orcid":false,"given":"Philipp","family":"Schwenkenbecher","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin Fritz","family":"Jendretzky","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gingele","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Grote-Levi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"M\u00f6hn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-481X","authenticated-orcid":false,"given":"Kurt-Wolfram","family":"S\u00fchs","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Eiz-Vesper","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8164-514X","authenticated-orcid":false,"given":"Britta","family":"Maecker-Kolhoff","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Hannover Medical School, Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Trebst","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5928-2343","authenticated-orcid":false,"given":"Martin W.","family":"H\u00fcmmert","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/14737175.2020.1820325","article-title":"Autologous hematopoietic stem-cell transplantation in neurological disorders: Current approach and future directions","volume":"20","author":"Das","year":"2020","journal-title":"Expert Rev. Neurother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s13311-017-0564-5","article-title":"Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis","volume":"14","author":"Atkins","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jneuroim.2008.04.030","article-title":"Autologous and allogeneic hematopoietic stem cell transplantation for Multiple Sclerosis: Perspective on mechanisms of action","volume":"197","author":"Sprangers","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/sj.bmt.1701129","article-title":"T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: Report on the first three patients","volume":"21","author":"Burt","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/art.1780400923","article-title":"Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy","volume":"40","author":"Cooley","year":"1997","journal-title":"Arthritis Rheum."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/096120339700600613","article-title":"Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration","volume":"6","author":"Marmont","year":"1997","journal-title":"Lupus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/ard.60.6.577","article-title":"Phase I\/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease","volume":"60","author":"Binks","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"eaba6884","DOI":"10.1126\/sciadv.aba6884","article-title":"Shattering barriers toward clinically meaningful MSC therapies","volume":"6","author":"Levy","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1073\/pnas.1820039116","article-title":"Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial","volume":"116","author":"Zubizarreta","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ana.23784","article-title":"Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation","volume":"73","author":"Darlington","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41409-018-0162-0","article-title":"Homeostatic proliferation leads to telomere attrition and increased PD-1 expression after autologous hematopoietic SCT for systemic sclerosis","volume":"53","author":"Arruda","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/imm.12129","article-title":"T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis","volume":"140","author":"Burman","year":"2013","journal-title":"Immunology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e127655","DOI":"10.1172\/jci.insight.127655","article-title":"Extensive intrathecal T cell renewal following hematopoietic transplantation for multiple sclerosis","volume":"5","author":"Harris","year":"2020","journal-title":"JCI Insight"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11899-019-00505-z","article-title":"Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: A Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists","volume":"14","author":"Das","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","article-title":"Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases","volume":"1","author":"Snowden","year":"2017","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.bbmt.2012.06.003","article-title":"Transplantation for autoimmune diseases in north and South America: A report of the Center for International Blood and Marrow Transplant Research","volume":"18","author":"Pasquini","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs. Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1352458516645670","article-title":"NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs","volume":"23","author":"Sormani","year":"2017","journal-title":"Mult. Scler."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2009.013458","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases: An observational study on 12 years\u2019 experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases","volume":"95","author":"Farge","year":"2010","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/14656566.2018.1446944","article-title":"Managing the side effects of multiple sclerosis therapy: Pharmacotherapy options for patients","volume":"19","author":"Rommer","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/brain\/awq245","article-title":"Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: Report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease","volume":"133","author":"Grauer","year":"2010","journal-title":"Brain"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41409-021-01277-y","article-title":"New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"56","author":"Burt","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8527","DOI":"10.1038\/s41598-021-87989-z","article-title":"Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Stadler","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/sj.bmt.1700944","article-title":"Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: First results of a pilot study","volume":"20","author":"Fassas","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/sj.bmt.1702180","article-title":"High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis","volume":"25","author":"Gregora","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1023\/A:1006686426090","article-title":"Autologous stem cell transplantation in progressive multiple sclerosis--an interim analysis of efficacy","volume":"20","author":"Fassas","year":"2000","journal-title":"J. Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1212\/WNL.56.8.1084","article-title":"MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS","volume":"56","author":"Saiz","year":"2001","journal-title":"Neurology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.57.1.62","article-title":"Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS","volume":"57","author":"Mancardi","year":"2001","journal-title":"Neurology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0041-1345(03)00071-X","article-title":"Phase I\/II trials of autologous peripheral blood stem cell transplantation in autoimmune diseases resistant to conventional therapy: Preliminary results from the Spanish experience","volume":"35","author":"Espigado","year":"2003","journal-title":"Transplant. Proc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood-2002-12-3908","article-title":"High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis","volume":"102","author":"Nash","year":"2003","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood-2003-03-0877","article-title":"Hematopoietic stem cell transplantation for progressive multiple sclerosis: Failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores","volume":"102","author":"Burt","year":"2003","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1212\/WNL.62.2.282","article-title":"Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS","volume":"62","author":"Saiz","year":"2004","journal-title":"Neurology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood-2004-08-3205","article-title":"Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: Impact on disease activity and quality of life","volume":"105","author":"Saccardi","year":"2005","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1007\/s10072-005-0514-6","article-title":"Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis","volume":"26","author":"Capello","year":"2005","journal-title":"Neurol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(09)70017-1","article-title":"Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: A phase I\/II study","volume":"8","author":"Burt","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bmt.2009.127","article-title":"Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM\/horse ATG and CY\/rabbit ATG","volume":"45","author":"Hamerschlak","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.exphem.2012.07.003","article-title":"Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis","volume":"40","author":"Shevchenko","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jns.2013.10.023","article-title":"Cognitive fatigue in individuals with multiple sclerosis undergoing immunoablative therapy and hematopoietic stem cell transplantation","volume":"336","author":"Berard","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.msard.2013.05.001","article-title":"Cognitive change and neuroimaging following immunoablative therapy and hematopoietic stem cell transplantation in multiple sclerosis: A pilot study","volume":"3","author":"Walker","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamaneurol.2014.3780","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): A 3-year interim report","volume":"72","author":"Nash","year":"2015","journal-title":"JAMA Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1212\/WNL.0000000000001329","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial","volume":"84","author":"Mancardi","year":"2015","journal-title":"Neurology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(16)30169-6","article-title":"Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: A multicentre single-group phase 2 trial","volume":"388","author":"Atkins","year":"2016","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000469655","article-title":"A Feasibility Study of the Full Outpatient Conduction of Hematopoietic Transplants in Persons with Multiple Sclerosis Employing Autologous Non-Cryopreserved Peripheral Blood Stem Cells","volume":"137","year":"2017","journal-title":"Acta Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/cei.13358","article-title":"Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: Real-world data from a single center","volume":"198","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/jnnp-2018-319446","article-title":"Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis","volume":"90","author":"Moore","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e13567","DOI":"10.1111\/ctr.13567","article-title":"Determine safety of outpatient chemotherapy and autotransplants using refrigerated, non-frozen grafts in persons with multiple sclerosis","volume":"33","author":"Gale","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1177\/1352458507076982","article-title":"The long-term effect of AHSCT on MRI measures of MS evolution: A five-year follow-up study","volume":"13","author":"Roccatagliata","year":"2007","journal-title":"Mult. Scler."},{"key":"ref_48","first-page":"643","article-title":"Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation","volume":"75","author":"Inglese","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1191\/1352458504ms1022oa","article-title":"Discordant functional and inflammatory parameters in multiple sclerosis patients after autologous haematopoietic stem cell transplantation","volume":"10","author":"Healey","year":"2004","journal-title":"Mult. Scler."},{"key":"ref_50","first-page":"50","article-title":"Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study","volume":"4","author":"Yazdanbakhsh","year":"2007","journal-title":"Iran. J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jneuroim.2010.07.013","article-title":"Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study","volume":"227","author":"Yamout","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archneurol.2010.248","article-title":"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis","volume":"67","author":"Karussis","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(11)70305-2","article-title":"Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study","volume":"11","author":"Connick","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/157488812804484648","article-title":"Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: An open label study","volume":"7","author":"Bonab","year":"2012","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Llufriu, S., Sep\u00falveda, M., Blanco, Y., Mar\u00edn, P., Moreno, B., Berenguer, J., Gabilondo, I., Mart\u00ednez-Heras, E., Sola-Valls, N., and Arnaiz, J.A. (2014). Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0113936"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jcyt.2016.08.007","article-title":"Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis","volume":"18","author":"Harris","year":"2016","journal-title":"Cytotherapy"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458517703802","article-title":"Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis","volume":"24","author":"Cohen","year":"2018","journal-title":"Mult. Scler."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/cns.12759","article-title":"Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy","volume":"23","author":"Dahbour","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ebiom.2018.02.002","article-title":"Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis","volume":"29","author":"Harris","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/08820139.2018.1504301","article-title":"Therapeutic Use of Intrathecal Mesenchymal Stem Cells in patients with Multiple Sclerosis: A Pilot Study with Booster Injection","volume":"48","author":"Sahraian","year":"2019","journal-title":"Immunol. Investig."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1093\/brain\/awaa333","article-title":"Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis","volume":"143","author":"Petrou","year":"2020","journal-title":"Brain"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1474-4422(21)00301-X","article-title":"Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): A phase 2, randomised, double-blind crossover trial","volume":"20","author":"Uccelli","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"113","DOI":"10.15283\/ijsc.2011.4.2.113","article-title":"Clinical outcome of 50 progressive multiple sclerosis patients treated with cellular therapy in iraq","volume":"4","author":"Hammadi","year":"2011","journal-title":"Int. J. Stem Cells"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5302120","DOI":"10.1155\/2016\/5302120","article-title":"Clinical Application of Autologous Adipose Stem Cells in Patients with Multiple Sclerosis: Preliminary Results","volume":"2016","author":"Stepien","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez, O., Izquierdo, G., Fern\u00e1ndez, V., Leyva, L., Reyes, V., Guerrero, M., Le\u00f3n, A., Arnaiz, C., Navarro, G., and P\u00e1ramo, M.D. (2018). Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I\/II safety and feasibility study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195891"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.3727\/096368914X685005","article-title":"The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis","volume":"23","author":"Li","year":"2014","journal-title":"Cell Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.msard.2014.08.002","article-title":"Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study","volume":"3","author":"Lublin","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12967-018-1433-7","article-title":"Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis","volume":"16","author":"Riordan","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2014.17986","article-title":"Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis","volume":"313","author":"Burt","year":"2015","journal-title":"JAMA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1212\/WNL.0000000000003660","article-title":"High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS","volume":"88","author":"Nash","year":"2017","journal-title":"Neurology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","article-title":"Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: Updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)","volume":"55","author":"Sharrack","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab versus interferon beta 1a as firstline treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: A post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_76","unstructured":"(2022, May 23). Available online: https:\/\/clinicaltrials.gov\/ct2\/results?term=stem+cell&cond=Multiple+Sclerosis&age_v=&gndr=&type=&rslt=&phase=2&Search=Apply."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458514541978","article-title":"Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party","volume":"21","author":"Greco","year":"2015","journal-title":"Mult. Scler."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e1732","DOI":"10.1212\/WNL.0000000000008394","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica","volume":"93","author":"Burt","year":"2019","journal-title":"Neurology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"102990","DOI":"10.1016\/j.msard.2021.102990","article-title":"A pilot trial of autologous hematopoietic stem cell transplant in neuromyelitis optic spectrum disorder","volume":"53","author":"Burton","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e000073","DOI":"10.1136\/bmjno-2020-000073","article-title":"Plegia to walking: AHSCBMT in severe NMOSD relapse","volume":"2","author":"Carlisle","year":"2020","journal-title":"BMJ Neurol. Open"},{"key":"ref_81","first-page":"26","article-title":"Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Neuromyelitis Optica in Singapore","volume":"27","author":"Hoay","year":"2018","journal-title":"Acta Neurol. Taiwan"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jocn.2015.02.007","article-title":"Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant","volume":"22","author":"Aouad","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/archneurol.2011.38","article-title":"Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica","volume":"68","author":"Matiello","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/NRL.0b013e3181b126e3","article-title":"A preliminary result of treatment of neuromyelitis optica with autologous peripheral hematopoietic stem cell transplantation","volume":"16","author":"Peng","year":"2010","journal-title":"Neurologist"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"102852","DOI":"10.1016\/j.msard.2021.102852","article-title":"Autologous hematopoietic stem cell transplantation in a pediatric patient with aquaporin-4 neuromyelitis optica spectrum disorder","volume":"50","author":"Khan","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/acn3.50843","article-title":"T-cell depleted HLA-haploidentical HSCT in a child with neuromyelitis optica","volume":"6","author":"Ceglie","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ana.24079","article-title":"Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica","volume":"75","author":"Greco","year":"2014","journal-title":"Ann. Neurol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"102110","DOI":"10.1016\/j.msard.2020.102110","article-title":"Allogeneic haematopoietic stem cell transplantation in a refractory case of neuromyelitis optica spectrum disorder","volume":"42","author":"Hau","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3389\/fneur.2020.00967","article-title":"IV\/IT hUC-MSCs Infusion in RRMS and NMO: A 10-Year Follow-Up Study","volume":"11","author":"Lu","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2174\/156720212803530708","article-title":"Human umbilical cord mesenchymal stem cell therapy on neuromyelitis optica","volume":"9","author":"Lu","year":"2012","journal-title":"Curr. Neurovasc. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/cns.12559","article-title":"Impact of Autologous Mesenchymal Stem Cell Infusion on Neuromyelitis Optica Spectrum Disorder: A Pilot, 2-Year Observational Study","volume":"22","author":"Fu","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"ref_92","unstructured":"ECTRIMS Online Library (2022, May 23). Rush C. 09\/12\/19; 279091; P731. Available online: https:\/\/onlinelibrary.ectrims-congress.eu\/ectrims\/2019\/stockholm\/279091\/carolina.rush.aggressive.and.refractory.mog.igg.associated.encephalomyelitis.html."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann. Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): A double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): A multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e1100","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders","volume":"9","author":"Ringelstein","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"ref_98","first-page":"e1184","article-title":"Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCENMO Study","volume":"98","author":"Siebert","year":"2022","journal-title":"Neurology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3389\/fimmu.2020.01317","article-title":"Autologous Stem Cell Transplantation in Common Variable Immunodeficiency: A Case of Successful Treatment of Severe Refractory Autoimmune Encephalitis","volume":"11","author":"Froehlich","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1191\/0961203304lu491oa","article-title":"High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus","volume":"13","author":"Lisukov","year":"2004","journal-title":"Lupus"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/ard.59.3.236","article-title":"Autologous stem cell transplantation in a case of treatment resistant central nervous system lupus","volume":"59","author":"Trysberg","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1191\/0961203306lu2269cr","article-title":"Autologous blood stem cell transplantation in refractory systemic lupus erythematodes with recurrent longitudinal myelitis and cerebral infarction","volume":"15","author":"Lehnhardt","year":"2006","journal-title":"Lupus"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s10875-015-0194-9","article-title":"Cerebral Vasculitis in X-linked Lymphoproliferative Disease Cured by Matched Unrelated Cord Blood Transplant","volume":"35","author":"Gray","year":"2015","journal-title":"J. Clin. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/jnnp.2007.118240","article-title":"Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation","volume":"78","author":"Vermeulen","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.1212\/NXI.0000000000000888","article-title":"A case of CIDP concurrent with MGUS IgG kappa responsive to autologous stem cell transplantation","volume":"7","author":"Colucci","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"ref_106","first-page":"760","article-title":"Autologous Hematopoietic Stem Cell Transplantation for Chronic Inflammatory Demyelinating Polyradiculoneuropathy","volume":"48","author":"Breiner","year":"2021","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1007\/s00415-020-10010-6","article-title":"Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"267","author":"Burt","year":"2020","journal-title":"J. Neurol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/ene.12896","article-title":"Devastating humoral CIDP variant remitted by autologous stem cell transplantation","volume":"23","author":"Scheibe","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/jnnp-2013-306014","article-title":"Autologous haematopoietic stem cell transplantation: A viable treatment option for CIDP","volume":"85","author":"Press","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/bmt.2013.18","article-title":"Sj\u00f6gren\u2019s syndrome associated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treated with autologous and subsequently allogeneic haematopoietic SCT (HSCT)","volume":"48","author":"Bregante","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1529-8027.2009.00221.x","article-title":"Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy","volume":"14","author":"Kazmi","year":"2009","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1600-0404.2007.00970.x","article-title":"No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy","volume":"117","author":"Axelson","year":"2008","journal-title":"Acta Neurol. Scand."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1212\/01.wnl.0000277266.53449.8b","article-title":"Nonmyeloablative autologous hematopoietic stem celltransplantation for refractory CIDP","volume":"69","author":"Oyama","year":"2007","journal-title":"Neurology"},{"key":"ref_114","first-page":"e1","article-title":"CIDP cured by allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Masszi","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp.72.1.127","article-title":"Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy","volume":"72","author":"Vermeulen","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"bcr09.2008.0927","DOI":"10.1136\/bcr.09.2008.0927","article-title":"Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP","volume":"2009","author":"Axelson","year":"2009","journal-title":"BMJ Case Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaneurol.2016.0113","article-title":"Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation","volume":"73","author":"Bryant","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.nmd.2016.09.020","article-title":"Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis-a case report","volume":"27","author":"Sandstedt","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2018.11.008","article-title":"Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: A case report","volume":"29","author":"Salazar","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/mus.24143","article-title":"Rare combination of myasthenia and motor neuronopathy, responsive to Msc-Ntf stem cell therapy","volume":"49","author":"Petrou","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archneurol.2009.28","article-title":"Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis","volume":"66","author":"Strober","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.nmd.2021.11.008","article-title":"Refractory CIDP successfully treated with autologous haematopoietic stem cell transplantation in a patient with monoclonal gammopathy of undetermined significance (MGUS) and rheumatoid arthritis","volume":"32","author":"Lopes","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s00415-021-10452-6","article-title":"Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation","volume":"268","author":"Urbain","year":"2021","journal-title":"J. Neurol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000488476","article-title":"Autologous Bone Marrow Transplantation for Polymyositis Combined with Myasthenia Gravis and Aplastic Anemia: A Case Report","volume":"10","author":"Mitsumune","year":"2018","journal-title":"Case Rep. Neurol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.bmt.1704550","article-title":"Acquired hemophilia-A in a patient with multiple sclerosis treated with autologous hematopoietic stem cell transplantation and interferon beta-1a","volume":"34","author":"Kaloyannidis","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/rheumatology\/keh637","article-title":"Fatal progressive systemic sclerosis following autologous stem cell transplantation and high-dose chemotherapy","volume":"44","author":"Trad","year":"2005","journal-title":"Rheumatology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2006-07-035766","article-title":"Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: Role of conditioning regimen used","volume":"109","author":"Loh","year":"2007","journal-title":"Blood"},{"key":"ref_128","first-page":"2052","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2013-307042","article-title":"Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis","volume":"85","author":"Azzopardi","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1191\/1352458505ms1109cr","article-title":"Brachial neuropathy after immunosuppression and stem cell transplantation for multiple sclerosis","volume":"11","author":"Walker","year":"2005","journal-title":"Mult. Scler."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.wneu.2019.12.169","article-title":"Brachial Plexitis After Stem Cell Transplant","volume":"136","author":"Zakaria","year":"2020","journal-title":"World Neurosurg."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41409-017-0048-6","article-title":"Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis","volume":"53","author":"Nguyen","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/mus.10485","article-title":"Acute neuropathies after peripheral blood stem cell and bone marrow transplantation","volume":"28","author":"Rabinstein","year":"2003","journal-title":"Muscle Nerve"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11060-012-0962-9","article-title":"Central and peripheral nervous system immune mediated demyelinating disease after allogeneic hemopoietic stem cell transplantation for hematologic disease","volume":"110","author":"Delios","year":"2012","journal-title":"J. Neurooncol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Cekdemir, D., Ozkan, H.A., Korkmaz, F., Ozgurel, Y., Kural, S., Tiryaki, N., and Gulbas, Z. (2021). Role of Therapeutic Plasma Exchange in Guillain-Barre Syndrome after Allogeneic Hematopoietic Stem Cell Transplant: Report of Two Cases. Clin. Lab., 67.","DOI":"10.7754\/Clin.Lab.2020.200613"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1007\/s10072-021-05500-y","article-title":"Steroid-responsive chronic inflammatory demyelinating polyradiculoneuropathy post-hematopoietic stem cell transplantation: A case report and literature review","volume":"42","author":"Zhao","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"426","DOI":"10.5692\/clinicalneurol.48.426","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy and hyponatremia in a patient with chronic graft versus host disease","volume":"48","author":"Wada","year":"2008","journal-title":"Rinsho Shinkeigaku"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/mus.23524","article-title":"Neuropathy in chronic graft-versus-host disease caused by donor T cells","volume":"46","author":"Haruki","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jns.12108","article-title":"CIDP-like neuropathies in graft versus host disease","volume":"20","author":"Cocito","year":"2015","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_140","first-page":"349","article-title":"Incapacitating peripheral neuropathy as a manifestation of chronic graft-versus-host disease","volume":"5","author":"Greenspan","year":"1990","journal-title":"Bone Marrow Transplant."},{"key":"ref_141","first-page":"411","article-title":"Exacerbation of inflammatory demyelinating polyneuropathy after bone marrow transplantation","volume":"7","author":"Openshaw","year":"1991","journal-title":"Bone Marrow Transplant."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1212\/WNL.43.8.1513","article-title":"Polyneuropathy complicating bone marrow and solid organ transplantation","volume":"43","author":"Amato","year":"1993","journal-title":"Neurology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.0919-6544.2002.00419_22_1.x","article-title":"Chronic demyelinating polyneuropathy in graft-versus-host disease following allogeneic bone marrow transplantation","volume":"22","author":"Nagashima","year":"2002","journal-title":"Neuropathology"},{"key":"ref_144","first-page":"748","article-title":"A case of asymmetric demyelinating neuropathy in a patient with chronic graft-versus-host disease","volume":"45","author":"Matsumoto","year":"2005","journal-title":"Rinsho Shinkeigaku"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.bmt.1705716","article-title":"Immune-mediated motor polyneuropathy after hematopoietic stem cell transplantation","volume":"40","author":"Suzuki","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.bbmt.2019.04.021","article-title":"Incidence, Risk Factors, and Outcome of Immune-Mediated Neuropathies (IMNs) following Haploidentical Hematopoietic Stem Cell Transplantation","volume":"25","author":"Ren","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/s41409-018-0202-9","article-title":"Chronic inflammatory demyelinating polyneuropathy in adult T-cell leukemia-lymphoma patients following allogeneic stem cell transplantation","volume":"53","author":"Hirano","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/mus.26118","article-title":"Delayed-onset inflammatory polyneuropathy without graft versus host disease after bone marrow transplantation","volume":"58","author":"Sinaei","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00508-016-0972-2","article-title":"Complete neurologic and cognitive recovery after plasmapheresis in a patient with chronic inflammatory demyelinating polyneuropathy after allogeneic hematopoietic stem cell transplantation","volume":"128","author":"Vogl","year":"2016","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.leukres.2011.11.025","article-title":"Immune-mediated peripheral neuropathy occurring simultaneously with recurrent graft-versus-host disease after allogenic hematopoietic stem cell transplantation","volume":"36","author":"Doi","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1590\/S0004-282X2007000400031","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy in chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Case report","volume":"65","author":"Lorenzoni","year":"2007","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_152","first-page":"410","article-title":"Chronic inflammatory demyelinating polyneuropathy: A previously unreported complication of bone marrow trans plantation","volume":"39","author":"Maguire","year":"1989","journal-title":"Neurology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/(SICI)1096-8652(199704)54:4<332::AID-AJH14>3.0.CO;2-D","article-title":"Chronic inflammatory demyelinating polyneuropathy in non-Hodgkin\u2019s lymphoma","volume":"54","author":"Griggs","year":"1997","journal-title":"Am. J. Hematol."},{"key":"ref_154","first-page":"322","article-title":"Peripheral neuropathy after autologous blood stem cell transplantation for multiple myeloma","volume":"8","author":"Boiron","year":"1994","journal-title":"Leukemia"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1085-9489.2005.00052.x","article-title":"Chronic inflammatory demyelinating polyneuropathy after autologous peripheral blood stem cell transplantation","volume":"10","author":"Peters","year":"2005","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_156","first-page":"758094","article-title":"Autoimmune Demyelinating Polyneuropathy as a Manifestation of Chronic Graft-versus-Host Disease after Adult Cord Blood Transplantation in a Patient with Chronic Lymphocytic Leukemia","volume":"2014","author":"Hogan","year":"2014","journal-title":"Case Rep. Hematol."},{"key":"ref_157","first-page":"1604","article-title":"Asymmetric peripheral neuropathy following reduced-intensity cord blood transplantation","volume":"49","author":"Sumi","year":"2008","journal-title":"Rinsho Ketsueki"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0887-8994(94)00097-L","article-title":"Neuromuscular complications of bone marrow transplantation","volume":"12","author":"Adams","year":"1995","journal-title":"Pediatr. Neurol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/mus.21023","article-title":"Muscle-specific kinase (MuSK) antibody-associated myasthenia gravis after bone marrow transplantation","volume":"38","author":"Atassi","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1034\/j.1600-0609.2002.02789.x","article-title":"Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40+ CD4+ T cells","volume":"69","author":"Kotani","year":"2002","journal-title":"Eur. J. Haematol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/sj.bmt.1700759","article-title":"Myasthenia gravis in association with allogeneic bone marrow transplantation: Clinical observations, therapeutic implications and review of literature","volume":"19","author":"Mackey","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM198312223092508","article-title":"Myasthenia gravis after bone-marrow transplantation. Evidence for a donor origin","volume":"309","author":"Smith","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.bmt.1701575","article-title":"Myasthenia gravis and polymyositis as manifestations of chronic graft-versus-host-disease","volume":"23","author":"Tse","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"ref_164","first-page":"503","article-title":"A patient of chronic graft-versus-host disease presenting simultaneously with polymyositis and myasthenia gravis","volume":"41","author":"Yanagihara","year":"2001","journal-title":"Rinsho Shinkeigaku"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.bmt.1701297","article-title":"Myasthenia gravis without chronic GVHD after allogeneic bone marrow transplantation","volume":"22","author":"Baron","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1600-0404.1997.tb00279.x","article-title":"Myasthenia gravis after allogeneic bone marrow transplantation. A case report and a review of the literature","volume":"96","author":"Zaja","year":"1997","journal-title":"Acta Neurol. Scand."},{"key":"ref_167","first-page":"155","article-title":"Myasthenia gravis after allogeneic bone marrow transplantation","volume":"14","author":"Shimoda","year":"1994","journal-title":"Bone Marrow Transplant."},{"key":"ref_168","first-page":"78","article-title":"Myasthenia gravis after BMT: Identification of patients at risk?","volume":"9","author":"Melms","year":"1992","journal-title":"Bone Marrow Transplant."},{"key":"ref_169","first-page":"129","article-title":"Widespread pulmonary fibrosis as a major clinical manifestation of chronic graft-versus-host disease","volume":"4","author":"Atkinson","year":"1989","journal-title":"Bone Marrow Transplant."},{"key":"ref_170","first-page":"22a","article-title":"Post bone marrow transplantation (BMT) myasthenia gravis: Evidence for acetylcholine receptor AchR0 abnormalitiy","volume":"64","author":"Seely","year":"1984","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1212\/WNL.36.8.1087","article-title":"Myasthenia gravis after allogeneic bone marrow transplantation: Relationship to chronic graft-versus-host disease","volume":"36","author":"Bolger","year":"1986","journal-title":"Neurology"},{"key":"ref_172","first-page":"435","article-title":"Myasthenia gravis after allogeneic bone marrow transplantation: Report of a new case and pathogenetic considerations","volume":"5","author":"Grau","year":"1990","journal-title":"Bone Marrow Transplant."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/sj.bmt.1702067","article-title":"Myasthenia gravis after allogeneic bone marrow transplantation for lymphoblastic lymphoma","volume":"24","author":"Dowell","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1532\/IJH97.06060","article-title":"Immune-mediated myelopathy following allogeneic stem cell transplantation","volume":"84","author":"Sakai","year":"2006","journal-title":"Int. J. Hematol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/archneurol.2008.522","article-title":"Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation","volume":"66","author":"Lu","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1212\/WNL.0b013e3181e6215d","article-title":"De novo relapsing-remitting multiple sclerosis following autologous stem cell transplantation","volume":"75","author":"Armstrong","year":"2010","journal-title":"Neurology"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3904\/kjim.2015.065","article-title":"A confusing case of multiple sclerosis and central nervous system graft versus host disease","volume":"31","author":"Yoon","year":"2016","journal-title":"Korean J. Intern. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1097\/RLU.0000000000001193","article-title":"FDG PET\/CT in Acute Tumefactive Multiple Sclerosis Occurring in a Case of Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"41","author":"Dong","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pediatrneurol.2014.07.007","article-title":"Neuromyelitis optica in an adolescent after bone marrow transplantation","volume":"52","author":"Baumer","year":"2015","journal-title":"Pediatr. Neurol."},{"key":"ref_180","first-page":"633","article-title":"Immune-mediated myelopathy after allogeneic marrow transplantation","volume":"15","author":"Openshaw","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2169\/internalmedicine.48.2003","article-title":"Encephalomyelitis mimicking multiple sclerosis associated with chronic graft-versus-host disease after allogeneic bone marrow transplantation","volume":"48","author":"Matsuo","year":"2009","journal-title":"Intern. Med."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Voss, M., and Bischof, F. (2010). Recurrent myelitis after allogeneic stem cell transplantation. Report of two cases. BMC Neurol., 10.","DOI":"10.1186\/1471-2377-10-76"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.braindev.2018.10.006","article-title":"Severe anti-GAD antibody-associated encephalitis after stem cell transplantation","volume":"41","author":"Nagai","year":"2019","journal-title":"Brain Dev."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12185-020-02859-0","article-title":"Limbic encephalitis with antibodies to N-methyl-D-aspartate (NMDA)-type glutamate receptor after allogeneic transplantation","volume":"112","author":"Toda","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jneuroim.2017.04.005","article-title":"Central and peripheral nervous system immune-mediated demyelinating disease after allogeneic hematopoietic stem cell transplantation","volume":"307","author":"Stefanou","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CND.0000000000000282","article-title":"Relapsing Bickerstaff Brainstem Encephalitis After Autologous Stem Cell Transplant","volume":"21","author":"Malhotra","year":"2020","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jneuroim.2018.08.003","article-title":"Neuronal surface antibody-mediated encephalopathy as manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"323","author":"Pirotte","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood.V91.7.2619","article-title":"Immune-mediated optic neuritis after unrelated allogeneic bone marrow transplantation","volume":"91","author":"Ooi","year":"1998","journal-title":"Blood"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/0883073811422831","article-title":"Catastrophic demyelinating encephalomyelitis after intrathecal and intravenous stem cell transplantation in a patient with multiple sclerosis","volume":"27","author":"Alderazi","year":"2012","journal-title":"J. Child. Neurol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jocn.2012.04.013","article-title":"Possible induction of acute disseminated encephalomyelitis (ADEM)-like demyelinating illness by intrathecal mesenchymal stem cell injection","volume":"20","author":"Kishk","year":"2013","journal-title":"J. Clin. Neurosci."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/14\/2165\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:48:08Z","timestamp":1760140088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/14\/2165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":190,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["cells11142165"],"URL":"https:\/\/doi.org\/10.3390\/cells11142165","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]}}}